Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3

Nooka AK, Strouse C, Larson SM, Lesokhin A, Varshavsky-Yanovsky A, Vesole DH, Koehne G, Soussou E, Sullivan ST, Cheng J, Raje N. Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3. Cancer. 2026 Jun 1;132(11):e70442. doi: 10.1002/cncr.70442. PMID: 42159085.


Related Posts